BioVie Starts Bezisterim SUNRISE-PD Trial in Early Parkinson’s
BioVie Inc. has initiated patient enrollment for its Phase 2 SUNRISE-PD clinical trial. This trial investigates the safety and...
Briacell Phase 2 Data: HR+ Breast Cancer Breakthrough
BriaCell Therapeutics Corp. announced positive survival data from its Phase 2 study of Bria-IMT™ combined with checkpoint inhibitors in...
Cln-978: Groundbreaking RA Therapy Enters Phase 1 Trial
Cullinan Therapeutics announced that the European Medicines Agency (EMA) approved its Clinical Trial Application for CLN-978, a novel CD19xCD3...
Macro Trends in Pharma: AI, Innovation, and the Impact on Outsourcing Strategy
At SCOPE Summit 2025, a panel discussion explored the industry’s macro trends, focusing on AI, innovation, and outsourcing strategies....
Heparegenix Secures €21.5M for Liver Regeneration
HepaRegeniX, a clinical-stage company developing therapies for liver diseases, completed a €21.5 million financing round with Wellington Partners. The...
Promising Efficacy Reported for TLX101 Glioma Therapy
Telix Pharmaceuticals announced preliminary positive Phase 2 results for TLX101, a targeted radiation therapy for recurrent high-grade glioma (brain...
Radiance Announces First Patient Dosing in Phase 1 Trial for ROR1 ADC
Radiance Biopharma has dosed the first patient in China for a Phase 1 clinical trial of RB-164™ (SYS6005), a...
Onvansertib in RAS+ Metastatic Colorectal Cancer: Phase 2 Trial Completes Enrollment
Cardiff Oncology has completed patient enrollment in its Phase 2 CRDF-004 trial. The trial is evaluating onvansertib combined with...
Lyell’s LYL314 Gets FDA RMAT Designation for Lymphoma Treatment
Lyell Immunopharma announced that the FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation to LYL314 for treating relapsed and/or...
Predictive Oncology’s Novel Approach to Abandoned Drugs
Predictive Oncology leveraged its AI-driven drug discovery platform and biobank of live-cell tumor samples to identify new potential uses...